Silva Pharmaceuticals Limited announcements
119 Dhaka Stock Exchange announcements for Silva Pharmaceuticals Limited (SILVAPHL) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (13).
- Dividend Declaration
The Board of Directors has recommended 0.10% cash dividend for general shareholders, including ICB, excluding others sponsors/directors for the year ended June 30, 2026. The sponsors and directors excluding ICB holds 34,198,500 shares and the general shareholders including ICB holds 102,301,500 shares. The total dividend amount of BDT 1,023,015 will be required to disburse to the general shareholders including ICB. Date of AGM: 29.12.2026, Time: 11:30 A.M. (cont.) (Cont. news of SILVAPHL): Venue: Hybrid System (Both physical and Digital Platform). Record Date: 01.12.2026. The Company has also reported EPS of Tk. (1.19), NAV per share of Tk. 14.29 and NOCFPS of Tk. 0.14 for the year ended June 30, 2026 as against Tk. (0.97), Tk. 15.48 and Tk. 0.10 respectively for the year ended June 30, 2025. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2026) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2026 at 3:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of August 2026. To view the details, please visit: https://www.dse.com.bd/api/auditorFilings/file/SILVAPHL-compressed.pdf?prefix=pdf%2Fpages%2Ffilings-auditors-opinion%2F
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of July, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharma,%20July%202026.pdf Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of June, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharma,%20June%202026.pdf Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of May, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharma,%20May%202026.pdf Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of April, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharma,%20April%202026.pdf Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of March, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharma,%20March%202026.pdf
- Q3 Financials
(Q3 Un-audited): EPS was Tk. (0.20) for January-March 2026 as against Tk. (0.14) for January-March 2025; EPS was Tk. (0.72) for July 2025-March 2026 as against Tk. (0.57) for July 2024-March 2025. NOCFPS was Tk. 0.09 for July 2025-March 2026 as against Tk. 0.26 for July 2024-March 2025. NAV per share was Tk. 14.76 as on March 31, 2026 and Tk. 15.48 as on June 30, 2025. Reasons for decreased in EPS, NOCFPS and NAVPS: (cont.) (Continuation news of SILVAPHL): During the period from July 1, 2025 to March 31, 2026, the Company's Net Profit after Tax and EPS decreased compared to the same period of the previous year, primarily due to a decline in sales volume. NOCFPS also decreased during the period, mainly attributable to lower sales and reduced collections from receivables. Furthermore, NAVPS per share declined as a result of the net loss incurred during the period. (end)
- Reschedule of Board Meeting under LR 16(1)
The Company has further informed that the meeting of the Board of Directors of the Company as per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on April 30, 2026 at 2:30 pm instead of earlier declared April 28, 2026 at 4:30 pm to consider, among others, Un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2026.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2026 at 4:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of February 28, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharmaceuticals_2026.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of ended 31 December, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharma_25.pdf
- Q2 Financials
(Q2 Un-audited): EPS was Tk. (0.26) for October-December 2025 as against Tk. (0.19) for October-December 2024; EPS was Tk. (0.52) for July-December 2025 as against Tk. (0.43) for July-December 2024. NOCFPS was Tk. 0.07 for July-December 2025 as against Tk. 0.11 for July-December 2024. NAV per share was Tk. 14.96 as on December 31, 2025 and Tk. 15.48 as on June 30, 2025. (cont.) (Cont. News of SILVAPHL): Reasons for deviation: EPS has decreased due to the decline in sales volume. NOCFPS has decreased compared to the same period of the previous year due to a decrease in the collection from receivables as well as sales. NAVPS has decreased due to net loss incurred during this period. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended 30 November, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SIlva_2025.pdf
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.